• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on 'Endocrine therapy in prostate cancer: time for re-appraisal of risks, benefits and cost-effectiveness?'.

作者信息

Shah S I A, Abel P D, Langley R E, Cafferty F H

出版信息

Br J Cancer. 2013 May 28;108(10):2192-3. doi: 10.1038/bjc.2013.210. Epub 2013 Apr 30.

DOI:10.1038/bjc.2013.210
PMID:23632479
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3670506/
Abstract
摘要

相似文献

1
Comment on 'Endocrine therapy in prostate cancer: time for re-appraisal of risks, benefits and cost-effectiveness?'.关于“前列腺癌的内分泌治疗：重新评估风险、益处和成本效益的时候了？”的评论
Br J Cancer. 2013 May 28;108(10):2192-3. doi: 10.1038/bjc.2013.210. Epub 2013 Apr 30.
2
Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?回复：前列腺癌的内分泌治疗：是时候重新评估风险、益处和成本效益了吗？
Br J Cancer. 2013 May 28;108(10):2194. doi: 10.1038/bjc.2013.211. Epub 2013 Apr 30.
3
Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?前列腺癌的内分泌治疗：是否需要重新评估风险、获益和成本效益？
Br J Cancer. 2013 Jan 15;108(1):9-13. doi: 10.1038/bjc.2012.523. Epub 2012 Nov 29.
4
RE: Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer.关于：对于临床淋巴结阳性前列腺癌采用雄激素剥夺疗法联合或不联合放射治疗的研究
J Natl Cancer Inst. 2015 Jul 23;107(9). doi: 10.1093/jnci/djv200. Print 2015 Sep.
5
Landmarks in hormonal therapy for prostate cancer.前列腺癌激素治疗的里程碑。
BJU Int. 2013 Mar;111(3):E12-3. doi: 10.1111/bju.12020_6.
6
Words of Wisdom. Re: Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer.智慧之言。关于：临床淋巴结阳性前列腺癌采用或不采用放射治疗的雄激素剥夺治疗。
Eur Urol. 2016 Feb;69(2):372-3. doi: 10.1016/j.eururo.2015.10.062.
7
Re: Per-Anders Abrahamsson. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010;57:49-59.回复：佩尔 - 安德斯·亚布拉罕松。间歇性雄激素抑制疗法在前列腺癌治疗中的潜在益处：文献系统综述。《欧洲泌尿外科杂志》2010年；57卷：49 - 59页。
Eur Urol. 2010 Jul;58(1):e4; author reply e5-6. doi: 10.1016/j.eururo.2010.03.032. Epub 2010 Mar 26.
8
Reply: Landmarks in hormonal therapy for prostate cancer.回复：前列腺癌激素治疗的里程碑。
BJU Int. 2013 Mar;111(3):E13-5. doi: 10.1111/bju.12020_7.
9
Re: Vincenzo Pagliarulo, Sergio Bracarda, Mario A. Eisenberger, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012;61:11–25.
Eur Urol. 2012 Jun;61(6):e59; author reply e60. doi: 10.1016/j.eururo.2012.02.048. Epub 2012 Feb 25.
10
Global update on the use of hormonal therapy for the management of high-risk prostate cancer: introduction.激素疗法用于高危前列腺癌管理的全球最新进展：引言
BJU Int. 2007 Jan;99 Suppl 1:1. doi: 10.1111/j.1464-410X.2007.06590.x.

引用本文的文献

1
Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?回复：前列腺癌的内分泌治疗：是时候重新评估风险、益处和成本效益了吗？
Br J Cancer. 2013 May 28;108(10):2194. doi: 10.1038/bjc.2013.211. Epub 2013 Apr 30.

本文引用的文献

1
Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).局部晚期和转移性前列腺癌患者接受黄体生成素释放激素激动剂或经皮雌激素治疗的心血管结局：随机、2 期 MRC PATCH 试验（PR09）。
Lancet Oncol. 2013 Apr;14(4):306-16. doi: 10.1016/S1470-2045(13)70025-1. Epub 2013 Mar 4.
2
Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?前列腺癌的内分泌治疗：是否需要重新评估风险、获益和成本效益？
Br J Cancer. 2013 Jan 15;108(1):9-13. doi: 10.1038/bjc.2012.523. Epub 2012 Nov 29.
3
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.胃肠外雌激素与联合雄激素剥夺疗法治疗转移性前列腺癌：第2部分。斯堪的纳维亚前列腺癌研究组（SPCG）5号研究的最终评估
Scand J Urol Nephrol. 2008;42(3):220-9. doi: 10.1080/00365590801943274.
4
Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer.一项多中心II期试验的早期激素数据，该试验使用经皮雌激素贴片作为局部晚期或转移性前列腺癌患者的一线激素治疗。
BJU Int. 2008 Aug;102(4):442-5. doi: 10.1111/j.1464-410X.2008.07583.x. Epub 2008 Apr 16.
5
Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism.经皮雌二醇治疗前列腺癌可降低血栓形成活性并预防血栓栓塞。
J Urol. 2005 Aug;174(2):527-33; discussion 532-3. doi: 10.1097/01.ju.0000165567.99142.1f.
6
Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer.当用作前列腺癌的单一药物治疗时，经皮雌二醇可改善骨密度。
J Urol. 2004 Dec;172(6 Pt 1):2203-7. doi: 10.1097/01.ju.0000145511.56476.00.
7
Leuprolide versus diethylstilbestrol for metastatic prostate cancer.亮丙瑞林与己烯雌酚治疗转移性前列腺癌的对比
N Engl J Med. 1984 Nov 15;311(20):1281-6. doi: 10.1056/NEJM198411153112004.
8
Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial.
Urology. 1986 Jan;27(1 Suppl):21-8.